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     Background.     Dutch people born between 1925 and 1945 were ineligible for vaccination 
with the inactivated poliovirus vaccine (IPV) introduced in 1957 and may have escaped 
natural infection because of reduced poliovirus circulation. We examined whether people with 
low or undetectable antibody levels are susceptible to infection and whether memory 
immunity provides protection against virus excretion. 
     Methods.     A total of 429 elderly participants were challenged with monovalent oral 
poliovirus vaccine (type 1 or 3) and followed for 8 weeks. Immune responses and virus 
excretion were compared for 4 groups, defined on the basis of seronegativity for poliovirus 
type 1 or 3, natural immunity, and IPV-induced immunity.  
     Results.     On the basis of the rapidity of the antibody response and the absence of 
immunoglobulin M, we saw clear evidence of memory immune responses in 33% of the 
participants without detectable antibodies against poliovirus type 1 and in 5% of the 
participants without detectable antibodies against poliovirus type 3. Fecal virus-excretion 
patterns were not significantly different for seronegative participants, regardless of whether 
they showed evidence of memory immunity.  
     Conclusions.     Rapid antibody responses after challenge with oral polio vaccine provide 
evidence for poliovirus-specific memory immunity in seronegative elderly people. However, in 
contrast to preexisting immunity, memory immunity does not protect against virus excretion. 
These results have important implications for the poliomyelitis-eradication initiative, in 
particular for future immunization policies after eradication has been achieved. 
     Presented in part: 13th European Congress of Clinical Microbiology and Infectious 
Diseases, Glasgow, United Kingdom, 10 13 May 2003 (abstract P683).  
     Financial support: Health Research and Development Council (ZonMw), The Netherlands.  
     Reprints or correspondence: Dr. F. Abbink, Dept. of Infectious Disease Epidemiology, 
National Institute of Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The 
Netherlands (f.abbink@rivm.nl). 
     Until the eradication of poliomyelitis is established throughout the world, countries that have 
been certified to be free of endemic poliovirus remain at risk for importation of wild-type (wt) 
polioviruses from regions of the world in which they still circulate. Reintroduction of the virus 
might also arise from laboratory stocks, environmental samples, or deliberate release [1, 2]. 
Moreover, recent unexpected findings in Hispaniola and Egypt have shown that outbreaks can 
be caused by revertant Sabin-vaccine strains [3, 4].  
     In The Netherlands, poliovirus vaccination with injectable inactivated poliovirus vaccine 
(IPV) was introduced in 1957 and was offered to everyone born in and after 1945. In general, 
the Dutch population is well protected against poliomyelitis [5]. However, despite the large 
number of people who are seropositive for antibodies against poliovirus and a national 
vaccination coverage rate of 97%, the threat of a poliomyelitis outbreak in The Netherlands is 
still real, especially because of a sociogeographically clustered group who choose to remain 
unvaccinated for religious reasons. Furthermore, the population born between 1925 and 1945 
has comparatively low poliovirus seroprevalence levels [5]. The latter group was ineligible for 
the routine vaccination program and might have escaped natural infection because of reduced 
poliovirus circulation; in addition, natural or vaccine-induced immunity may have waned. It is 
unclear whether everyone with a low or undetectable level of antibodies is susceptible to 
infection and is therefore at risk during an outbreak. Some people, particularly the elderly, may 
be protected by memory immunity (an accelerated immune response after challenge), 
because the immune system was previously primed. Previous studies have suggested that 
protection against poliovirus infection whether due to previous experience with wt 
polioviruses or with vaccine strains may be present in the absence of detectable serum 
antibodies [6 10].  
     The main purpose of the present study was, therefore, to find evidence of memory 
immunity in seronegative elderly people after challenge with oral polio vaccine (OPV) and to 
examine the protective efficacy of memory immunity. Immune responses and virus excretion 
were compared for 4 groups of participants, defined on the basis of seronegativity for 
poliovirus type 1 or 3, natural immunity, and IPV-induced immunity.  
PARTICIPANTS, MATERIALS, AND METHODS  
     Study design.     Elderly people born in the birth cohort presumed to be at risk (1925
1945; hereafter, "the risk birth cohort") and IPV recipients born in the adjacent birth cohort 
(1945 1950) were challenged with a standardized dose of monovalent OPV type 1 (MOPV-1) 
or type 3 (MOPV-3) and were followed for 8 weeks. An outline of the study design is given in 
figure 1. All inhabitants of Tiel from the risk birth cohort (n = 6175) and a random sample of 
inhabitants from the adjacent birth cohort (n = 850) were invited to participate in the screening. 
Tiel is a medium-sized town in the center of the country and has 40,000 inhabitants and 
average rates of vaccination coverage. The purpose of the screening was to assess levels of 
antibodies against poliovirus types 1 3. During screening, participants signed an informed-
consent form, provided a serum sample (10 mL), and completed a questionnaire. Within 8 
weeks, the participants received written information about their antibody levels. Those who 
were not selected for the second part of the study and had antibody levels that were 
inadequate to provide protection were advised to obtain a booster inoculation of diphtheria, 
tetanus, and inactivated poliovirus vaccine (DT-IPV).  
     For the second part of the study, the OPV challenge, participants were selected on the 
basis of their prechallenge serum neutralizing antibody titers, IPV vaccination histories, and 
exclusion criteria. Those with major medical problems (particularly immunodeficiency 
disorders) and with a history of OPV vaccination were excluded from the study. The selected 
participants were assigned to 1 of the 4 following groups: those seronegative for poliovirus 
type 1 with no history of vaccination (SN-1), those seronegative for poliovirus type 3 with no 
history of vaccination (SN-3), those seropositive for all 3 poliovirus types with no history of 
vaccination (i.e., those who were naturally immune [NI]), and those seropositive for all 3 
poliovirus types with a documented history of a full series of IPV vaccinations and no history of 
OPV vaccination (IPVV). The NI and IPVV participants were randomly assigned to be 
challenged with either MOPV-1 (hereafter, "NI-1" and "IPVV-1") or MOPV-3 (hereafter, "NI-3" 
and "IPVV-3"), so that 6 groups were used in the analyses. At the first appointment, 
prechallenge (day 0) serum samples were obtained, after which OPV was administered. Stool 
samples were obtained on days 3, 7, 14, 21, 28, 35, 42, 49, and 56 after challenge. Serum 
samples were obtained on days 7, 28, and 56 after challenge. On completion of their 
participation, the participants who belonged to the SN-1 and SN-3 groups were offered a full 
series of inoculations with DT-IPV. The Medical Ethics Committee of the Dutch Organization 
for Applied Scientific Research (Leiden, The Netherlands) approved the study proposal.  
  
Figure 1   
Study population, participation rates (pr), and design Tiel, The Netherlands, 1999. IPV, 
inactivated poliovirus vaccine; IPVV-1 and -3, participants seropositive for all 3 
poliovirus types with a documented history of a full series of IPV vaccinations and no 
history of OPV vaccination who were challenged with MOPV-1 and -3, respectively; 
MHS, municipal health services; MOPV-1 and -3, monovalent OPV type 1 and 3, 
respectively; NI-1 and -3, participants considered to be naturally immune who were 
challenged with MOPV-1 and -3, respectively; OPV, oral polio vaccine; SN-1 and -3, 
participants seronegative for poliovirus type 1 and 3, respectively, with no history of 
vaccination. 
     Vaccines.     To keep the study feasibly small, only 2 vaccines, for poliovirus types 1 and 3, 
were used in the challenge experiments. Poliovirus types 1 and 3 are the most important 
types, having caused epidemics during recent decades. MOPV-1 and MOPV-3 (Oral-Virelon 
T1 Type 1 and Oral-Virelon T1 Type 3; Chiron Behring) contained 5.8 × 105 TCID50 of 
poliovirus type 1 and 1.0 × 104 TCID50 of poliovirus type 3, respectively, according to the 
manufacturer. Vaccine was received from the manufacturer 1 week before the start of the 
challenge study (April 1999), was stored at 4°C until use, was administered orally in 1-mL 
volumes, and was used within the shelf-life expiration date assigned by the manufacturer 
(October 1999).  
     Collection of samples.     At each of the 5 visits, venous blood (10 mL) was obtained for 
antibody determinations (neutralizing antibody titers and poliovirus type specific IgA and IgM). 
Serum was separated and stored at -20°C until testing. Stool samples, collected to determine 
viral excretion, were collected at home and kept in the refrigerator until delivery or were sent 
immediately by regular mail to the National Institute of Public Health and the Environment. 
Virus isolation was performed by use of L20B cells, as described elsewhere [11].  
     Serological assays.     All serum samples were tested for poliovirus antibodies by use of 
an ELISA developed by Herremans et al. (PoBi assay; [12]). Titers obtained in the PoBi assay 
and the standard neutralizing antibody test (NT) are closely correlated [12]. Seronegativity for 
poliovirus types 1 and 3 was confirmed by a standard NT, as recommended by the World 
Health Organization (WHO) [11]. The Sabin strains of poliovirus types 1 and 3 were used for 
this purpose. Furthermore, a standard NT was used to confirm all PoBi assay results in the 
SN-3 group. In brief, serial 2-fold dilutions of serum samples and 100 50% cell-culture infective 
doses of virus were incubated in 96-microwell plates (Greiner) for 3 h at 37°C. After 
incubation, 1.75 × 104 HEp-2C cells were added to each well. After 6 days of incubation at 
37°C, the plates were read. The results are given as log2 reciprocal titers, expressed as the 
reciprocal of the greatest dilution showing complete neutralization of the cytopathic effect of 
100% cell-culture infectious doses. A titer of 1 : 8 (i.e., a log2 titer of 3) or more is a generally 
accepted and frequently used indication of protective immunity. A rapid (i.e., memory) 
response was defined as a 4-fold increase in neutralizing antibody titer occurring during the 
first 7 days after OPV challenge [13].  
     A total of 42 participants (10%) were excluded from the analysis because of 
misclassification. Misclassifications were caused by small differences between the antibody 
titers determined during screening and the prechallenge antibody titers. All serum samples 
were tested for poliovirus-specific IgA and for poliovirus-specific IgM by use of ELISAs, as 
described elsewhere [14, 15].  
RESULTS  
     Participation.     In total, 7025 people were invited to the screening, and 1847 people 
(26%) participated. The level of participation in the challenge study (for the entire period of 8 
weeks) was much greater, with an average participation rate of 48%. Figure 1 shows the 
number of participants in each group and the corresponding participation rates.  
     Serum neutralizing antibody response after OPV challenge.     The percentage of 
participants experiencing a 4-fold increase in neutralizing antibody titers for poliovirus types 
1 3 (hereafter, the "responders") after challenge with either MOPV-1 or MOPV-3 are given in 
table 1 for SN-1, SN-3, NI-1, NI-3, IPVV-1, and IPVV-3 participants, stratified by prechallenge 
antibody titer. The postchallenge antibody responses were classified as rapid ( 4-fold 
increase occurring within 7 days), slow ( 4-fold increase occurring between days 8 and 56) 
and none (<4-fold increase during the study period).  
Table 1.     Percentages of participants experiencing a 4-fold increase in serum 
neutralizing antibody titer for poliovirus types 1, 2, and 3, stratified by prechallenge 
(day 0) antibody titers (PCT) and rapidity of response, and prechallenge sample sizes, 
in seronegative (SN), inactivated poliovirus vaccine vaccinated (IPVV), and naturally 
immune (NI) participants challenged with monovalent oral polio vaccine type 1 (MOPV-
1) or 3 (MOPV-3) Tiel, The Netherlands, 1999.  
 
Poliovirus type 1 Poliovirus type 2 Poliovirus type 3 
Rapidity of response Rapidity of response Rapidity of response 
Vaccine 
challenge,  
participant 
category 
No. of 
participants 
Rapid 
(day 7) 
Slow 
(day 
8 56) None 
No. of 
participants 
Rapid 
(day 7) 
Slow 
(day 
8 56) None 
No. of 
participants 
Rapid 
(day 7) 
Slow 
(day 
8 56) None 
MOPV-1 
challenge 
            
     SN-1 
total 
98 33 60 7 25 0 56 44 48 6 31 63 
          PCT 
of 0 
55 33 56 11 0 ... ... ... 0 ... ... ... 
          PCT 
of 1 2 
43 33 65 2 25 0 56 44 48 6 31 63 
     IPVV-1 
total 
43 12 21 67 34 3 9 88 38 5 21 74 
          PCT 
of 3 6 
29 17 31 52 23 4 13 83 31 6 26 68 
          PCT 
of 7 
14a ... ... ... 11a ... ... ... 7a ... ... ... 
     NI-1 total 50 10 36 54 49 2 22 76 43 0 21 79 
          PCT 
of 3 6 
46 11 39 50 42 2 26 72 42 0 21 79 
          PCT 
of 7 
4a ... ... ... 7a ... ... ... 1a ... ... ... 
MOPV-3 
challenge 
            
     SN-3 
total 
10 30 20 50 43 9 49 42 103 5 68 27 
          PCT 
of 0 
... ... ... ... 0 ... ... ... 57 4 75 21 
          PCT 
of 1 2 
10 30 20 50 43 9 49 42 46 7 59 34 
     IPVV-3 
total 
47 6 0 94 46 0 22 78 45 0 7 93 
          PCT 
of 3 6 
37 8 0 92 38 0 26 74 39 0 8 92 
          PCT 
of 7 
10a ... ... ... 8a ... ... ... 6a ... ... ... 
     NI-3 total 55 0 7 93 53 0 15 85 44 0 25 75 
          PCT 
of 3 6 
45 0 9 91 45 0 18 82 44 0 25 75 
          PCT 
of 7 
10a ... ... ... 8a ... ... ... 0 ... ... ... 
NOTE.     Data are percentages of participants, unless otherwise noted. Boldface values 
represent serological responses to the same type of virus as that used in the challenge. IPVV-
1 and -3, participants seropositive for all 3 poliovirus types with a documented history of a full 
series of IPV vaccinations and no history of OPV vaccination who were challenged with 
MOPV-1 and -3, respectively; NI-1 and -3, participants considered to be NI who were 
challenged with MOPV-1 and -3, respectively; SN-1 and -3, participants seronegative for 
poliovirus type 1 and 3, respectively, with no history of vaccination.  
     
a
 Excluded from the analysis because booster responses could not be evaluated for those 
with a PCT of 7 (the greatest dilution tested was 1 : 256 [log2 titer of 8]). 
 
     Most of the seronegative participants challenged with OPV experienced a slow (i.e., 
primary) antibody response 60% of the SN-1 participants after MOPV-1 challenge and 68% 
of the SN-3 participants after MOPV-3 challenge. In contrast, 33% of the SN-1 participants and 
only 5% of the SN-3 participants experienced the expected rapid (i.e., secondary) antibody 
response after challenge. The remainder did not experience an antibody response to the 
challenge.  
     Overall, 93% of the SN-1 participants experienced a 4-fold increase in neutralizing 
antibody titers for poliovirus type 1 after challenge with MOPV-1, which was significantly more 
than the 33% of the IPVV-1 participants and the 46% of the NI-1 participants. The groups 
challenged with MOPV-3 showed a similar pattern but with a lower rate of 4-fold increases in 
neutralizing antibody titer. In the 2 seronegative groups, lower prechallenge antibody titers 
were not associated with a higher rate of 4-fold increases in neutralizing antibody titer.  
     The serological data showed clear evidence of cross-reactivity. A substantial percentage of 
the participants challenged with MOPV-1 experienced a 4-fold increase in neutralizing 
antibody titers for poliovirus types 2 and 3 as well. Similar results were found for the 
participants challenged with MOPV-3. The highest percentages of participants experiencing a 
cross-reactive 4-fold increase in neutralizing antibody titer were observed for poliovirus type 
2 in the 2 seronegative groups 56% of the SN-1 participants and 49% of the SN-3 
participants. In addition, booster responses for the virus types other than the one used in the 
challenge were also found for the IPVV and NI participants (up to 26%).  
     IgM response.     Poliovirus-specific IgM was undetectable in all serum samples from the 
rapid responders and was almost absent in the serum samples from the slow responders 
experiencing a 4-fold increase in neutralizing antibody titer on day 56 (table 2). Poliovirus-
specific IgM was, however, detectable in serum samples from slow responders experiencing a 
4-fold increase in neutralizing antibody titer on day 28. The greatest prevalences were found 
in the 2 seronegative groups.  
Table 2.      Percentages of participants positive for IgM, stratified by rapidity of 
response (day 7, 28, or 56), and prechallenge (day 0) sample sizes, in seronegative 
(SN), inactivated poliovirus vaccine vaccinated (IPVV), and naturally immune (NI) 
participants who were challenged with monovalent oral polio vaccine type 1 (MOPV-1) 
or 3 (MOPV-3) Tiel, The Netherlands, 1999.  
 
Rapid responder (day 7) Slow responder 
Day 28 Day 56 
Participant category 
No. of  
participants 
IgM  
positive, % No. of  
participants 
IgM  
positive, % 
No. of  
participants 
IgM  
positive, % 
SN-1 (n = 103) 32 0 57 35 7 0 
SN-3 (n = 115) 5 0 65 17 11 9 
IPVV-1 (n = 29) 5 0 9 11 0 ... 
IPVV-3 (n = 39) 0 ... 2 0 1 0 
NI-1 (n = 46) 5 0 15 7 3 0 
NI-3 (n = 44) 0 ... 9 0 2 0 
 
NOTE.     IPVV-1 and -3, participants seropositive for all 3 poliovirus types with a documented 
history of a full series of IPV vaccinations and no history of OPV vaccination who were 
challenged with MOPV-1 and -3, respectively; NI-1 and -3, participants considered to be NI 
who were challenged with MOPV-1 and -3, respectively; SN-1 and -3, participants 
seronegative for poliovirus type 1 and 3, respectively, with no history of vaccination.  
 
     IgA response.     As expected, poliovirus-specific IgA was absent in the majority of serum 
samples from seronegative participants before challenge and increased significantly after 
challenge, with a peak on day 28 (table 3). Of the IPVV and NI participants, the majority were 
already seropositive for IgA before challenge. 
Table 3.      Percentages of participants positive for IgA, in seronegative (SN), 
inactivated poliovirus vaccine vaccinated (IPVV), and naturally immune (NI) 
participants who were challenged with monovalent oral polio vaccine type 1 (MOPV-1) 
or 3 (MOPV-3) Tiel, The Netherlands, 1999.  
 
IgA positive, % Participant category 
Day 0 Day 7 Day 28 Day 56 
SN-1 (n = 103) 3 6 69 63 
SN-3 (n = 115) 5 19 60 46 
IPVV-1 (n = 29) 69 62 86 68 
IPVV-3 (n = 39) 97 87 89 97 
NI-1 (n = 46) 59 59 88 84 
NI-3 (n = 44) 86 88 93 82 
 
NOTE.     IPVV-1 and -3, participants seropositive for all 3 poliovirus types with a documented 
history of a full series of IPV vaccinations and no history of OPV vaccination who were 
challenged with MOPV-1 and -3, respectively; NI-1 and -3, participants considered to be NI 
who were challenged with MOPV-1 and -3, respectively; SN-1 and -3, participants 
seronegative for poliovirus type 1 and 3, respectively, with no history of vaccination.  
     Poliovirus excretion.     Quantitative data on virus excretion are shown in figures 2 and 3. 
Most seronegative participants challenged with OPV excreted virus for a considerable period 
of time (figures 2A and 3A). In the SN-1 group, the highest percentage (81%) excreted 
poliovirus type 1 three days after challenge, whereas, in the SN-3 group, the highest 
percentage (75%) excreted poliovirus type 3 seven days after challenge. Although the 
maximum excretion rates for poliovirus type 3 were observed somewhat later, compared with 
those for poliovirus type 1, overall, the percentage of seronegative participants who excreted 
poliovirus type 3 was higher during the entire study period. 
Figure 2 Percentage excreting poliovirus (bars), duration of poliovirus excretion, 
and quantity of poliovirus type 1 per gram of stool (expressed as log10 mean titers 
[e.g., 4 = 104]) (solid lines), for participants seronegative for poliovirus type 1 (SN-1) 
(A), participants seropositive for all 3 poliovirus types with a documented history of a 
full series of inactivated poliovirus vaccine (IPV) vaccinations and no history of oral 
polio vaccine (OPV) vaccination (IPVV-1) (B), and naturally immune (NI-1) participants 
(C) challenged with 5.8 × 105 TCID50 of monovalent OPV type 1, stratified by rapidity of 
serologic response Tiel, The Netherlands, 1999. 
 
 
Figure 3 Percentage excreting poliovirus (bars), duration of poliovirus excretion, 
and quantity of poliovirus type 3 per gram of stool (expressed as log10 mean titers 
[e.g., 4 = 104]) (solid lines), for participants seronegative for poliovirus type 3 (SN-3) 
(A), participants seropositive for all 3 poliovirus types with a documented history of a 
full series of inactivated poliovirus vaccine (IPV) vaccinations and no history of oral 
polio vaccine (OPV) vaccination (IPVV-3) (B), and naturally immune (NI-3) participants 
(C) challenged with 1.0 × 104 TCID50 of monovalent OPV type 3, stratified by rapidity of 
serologic response Tiel, The Netherlands, 1999. 
 
 
     Comparison of the excretion rates for poliovirus type 1 showed that rapid and slow 
responders excreted similar amounts of virus. For poliovirus type 3, the excretion rates of the 
rapid and slow responders showed a consistent pattern: the slower the increase in neutralizing 
antibody titer, the higher the percentage of individuals excreting poliovirus type 3. 
Furthermore, in both the SN-1 and SN-3 groups, there was no relationship between 
prechallenge titers and (1) duration of excreting or (2) the percentage of participants excreting 
virus (data not shown).  
     Figure 2B and 2C and figure 3B and 3C clearly show the effect of preexisting antibodies on 
virus excretion. As expected, only 17% of the IPVV-1 participants and 18% of the IPVV-3 
participants excreted challenge virus, and the time of excretion was short (maximum, 28 days), 
compared with that in the 2 seronegative groups. Similar results were found for the NI 
participants. After challenge, only 22% of the NI-1 participants and 30% of the NI-3 
participants excreted challenge virus, and the period of excretion was relatively short.  
     Finally, the mean titers of virus isolated from stool were not significantly different between 
poliovirus type 1 excreters and poliovirus type 3 excreters when SN-1, SN-3, IPVV, or NI 
participants were compared. There was no relationship between the titers of virus shed in stool 
and day after challenge.  
DISCUSSION  
     In the present study, we found clear evidence of memory immunity in 33% of the elderly 
population without detectable antibodies against poliovirus type 1 (i.e., the SN-1 group) and in 
5% of the elderly population without detectable antibodies against poliovirus type 3 (i.e., the 
SN-3 group). The complete absence of IgM responses among rapid responders is 
supplementary evidence for the existence of memory immunity, because IgM antibodies are 
characteristic of primary antibody responses. In contrast to preexisting antibodies, memory 
immunity, as measured in persons seronegative for the type of virus they are challenged with, 
does not protect against virus excretion. These results have important implications for the 
poliomyelitis-eradication initiative, in particular for future immunization policies after eradication 
has been achieved.  
     Our study was aimed at the elderly because lower seroprevalences were found in that age 
group [5]. To our knowledge, there are no published studies that have evaluated the antibody 
response among the elderly after artificial OPV challenge. All OPV challenge studies 
conducted to date have focused on children. However, it is important to mention that some of 
these studies have suggested that people with low or undetectable serum antibody levels are 
probably not in danger of developing clinical poliomyelitis, because they possess memory 
immunity [16, 17]. The concept of immunologic hyperreactivity, or immunologic memory, was 
invoked almost 50 years ago [18]. As this concept developed [19, 20], it was suggested that, 
when the level of neutralizing antibodies fell below detectability, immunologic memory would 
persist irreversibly, so that restimulation by vaccine or infection would result in a rapid and 
strong increase in antibody levels. This secondary response to infection was postulated to be 
rapid enough to protect against virus replication and paralytic disease. In other words, the 
individual who has immunologic memory, even if he or she does not have (detectable) 
circulating antibodies at the time of exposure, may respond sufficiently rapidly to block 
invasion of the central nervous system and prevent viral excretion in feces. In the present 
study, a rapid (i.e., memory) response was defined as a 4-fold increase in neutralizing 
antibody titer occurring within 7 days after OPV challenge, which is the definition most 
commonly used [13].  
     Our study found few rapid responders 33% of the SN-1 participants and 5% of the SN-3 
participants. However, it is likely that this is an underestimation of the true effect, because 
antibody responses considered to be indicative of a rapid response were evaluated on day 7 
only. Our choice of day 7 was based on the definition of memory response and on the results 
of studies by Herremans et al. [21] and Rumke et al. [10], in which IPV was used as the 
challenge virus.  
     Noteworthy is the small number of rapid responders observed after challenge with MOPV-
3. Although one might argue that this finding was caused by the fact that the potency of the 
type 3 vaccine used in the present study was less than that recommended by the WHO for 
trivalent OPV, our results on virus-excretion patterns clearly show that this was not the case. 
After all, no differences in the virus-excretion patterns of the 2 seronegative groups were 
observed. Furthermore, the OPV type 3 in trivalent OPV is more highly dosed, compared with 
monovalent OPV type 3, to balance the dominance of OPV type 2 [22]. Finally, our results are 
consistent with those of an earlier study in children who received trivalent OPV; this study 
showed that rates of seroconversion are lowest for poliovirus type 3 [23].  
     The small number of antibody responses ( 4-fold increase) among the IPVV and NI 
participants in the present study seems to indicate an excellent level of protection there was 
no increase in neutralizing antibody titer because poliovirus replication was absent. In these 
participants, titers of antibody (both IgG and IgA) against poliovirus were already present 
before OPV challenge. As described elsewhere [24], secretory IgA provides a local barrier to 
poliovirus infection, although the level of antibody that provides protection is not known. The 
presence of IgA in the serum of the IPVV participants can be explained by the fact that 
poliovirus was still endemic during the initial period of their lives, and so infection with 
poliovirus might have occurred. Because IPV vaccination alone is not able to induce IgA, 
previous mucosal priming with live virus is needed. Subsequently, IPV is able to boost IgA 
responses, which explains the higher prevalence of IgA found in the IPVV participants, 
compared with that in the NI participants [21].  
     The prevalence of antibody responses was somewhat greater for the NI participants, which 
can be explained by the lower prechallenge antibody levels. Previous studies [8, 9] have 
suggested that higher prechallenge antibody levels prevent enteric reinfection by a vaccine 
virus after a challenge dose is administered, whereas lower prechallenge antibody levels 
permit boosting infection to take place.  
     In most previous challenge studies that used monovalent vaccine, serological responses 
were described only for the type of virus used for the challenge. In the present study, the 
existence of cross-reactivity has been clearly shown. In the seronegative groups, as many as 
66% of the participants were found to experience a primary response for 1 of the 2 poliovirus 
types other than the challenge type. Although most participants experienced a primary 
response, we even found a noticeable number of participants who experienced a rapid 
response for a poliovirus type other than the challenge type. The high level of cross-reactivity 
observed in the present study is not a PoBi assay artifact, because all results in the SN-3 
group and a sample of the results in the SN-1 group (25%) were confirmed by a standard NT. 
Moreover, this surprising level of cross-reactivity has not previously been observed with the 
PoBi technique [12]. A potential explanation is that elderly people have previously come into 
contact with the other types, given that poliovirus was endemic during their lives. These cross-
reactive responses we measured could partly be secondary responses.  
     A unique feature of the present study was the challenge with OPV instead of the more 
commonly used IPV; challenge with OPV simulates a more natural route of infection and 
provided us with the opportunity to monitor virus excretion in feces as a parameter of 
protection. Failure to detect viral multiplication in the intestine (by excretion of virus in stool) 
after challenge with poliovirus indirectly demonstrates the presence of intestinal immunity. 
Conversely, fecal shedding of virus comparable with that seen in a nonimmune individual 
suggests absence of intestinal immunity and neutralization of the virus. One of the most 
striking results of the present study is that similar fecal virus-excretion patterns were found for 
the rapid and slow responders in the 2 seronegative groups. Furthermore, 80% of the 
seronegative participants excreted virus after challenge with OPV, and, for 85% 100% of 
those who showed a memory response, virus excretion continued for up to 8 weeks after 
challenge. The effect that preexisting antibodies has on virus excretion was clearly shown: 
only 20% of the IPVV participants and 25% of the NI participants excreted challenge virus, 
and the period of excretion was relatively short.  
     Extrapolation of our findings to the general population results in estimates that at least 6% 
(for poliovirus type 1) and 15% (for poliovirus type 3) of the elderly population of The 
Netherlands is at risk for infection [5]. In addition to the individual risk of infection, the risk of 
the circulation of poliovirus among the population should be emphasized, because the vast 
majority of those protected by memory immunity will excrete virus for a substantial period of 
time after exposure. Moreover, virus excretion will be considerably higher after exposure to wt 
poliovirus, compared with that after exposure to OPV.  
     It can be debated whether protection against virus excretion (as measured in the present 
study) is correlated with protection against disease. Although the implications of our results will 
manifest themselves only in the event of the reintroduction of the virus and the risk of 
reintroduction is small in the event of an epidemic, we would consider vaccination for those 
born between 1925 and 1945 who live in the Bible Belt of The Netherlands.  
     In summary, on the basis of the rapidity of the antibody response and the absence of IgM, 
we conclude that there is clear evidence for the existence of memory immunity in 33% of the 
elderly population without detectable antibodies against poliovirus type 1 and in 5% of the 
elderly population without detectable antibodies against poliovirus type 3. However, the 
majority of seronegative individuals, whether showing evidence of memory immunity or not, 
are a threat to the poliomyelitis-eradication initiative, because they are not protected against 
virus replication after challenge with OPV.  
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